Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1481 to 1490 of 1856 total matches.
Capmatinib (Tabrecta) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
cannot tolerate the 200-mg dose. A 30-day
supply of Tabrecta costs about $23,120.3
CONCLUSION — In one ...
The FDA has granted regular approval to the oral
kinase inhibitor capmatinib (Tabrecta – Novartis) for
treatment of metastatic non-small cell lung cancer
(NSCLC) in adults whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET)
exon 14 skipping. MET exon 14 skipping mutations
occur in 3-4% of NSCLC cases. The drug received
accelerated approval for the same indication in 2020
based on initial overall response rates and duration
of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6 doi:10.58347/tml.2023.1674d | Show Introduction Hide Introduction
In Brief: A New Indication for Tenecteplase (TNKase)
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
, with higher scores indicating
greater disability) 90–120 days after treatment. At the
time of data cutoff ...
The tissue plasminogen activator (tPA) tenecteplase
(TNKase – Genentech) has been approved by the FDA
for treatment of acute ischemic stroke in adults. It
is the second tPA to be approved in the US for this
indication; alteplase (Activase) was approved in
1996. Tenecteplase was approved in 2000 to reduce
the risk of death associated with acute ST-elevation
myocardial infarction (STEMI).
Med Lett Drugs Ther. 2025 Apr 28;67(1727):71-2 doi:10.58347/tml.2025.1727d | Show Introduction Hide Introduction
Perinatal Toxicity of Cocaine
The Medical Letter on Drugs and Therapeutics • Jun 03, 1988 (Issue 767)
were still present in 10 infants at
eight to 19 days, but only one by three to 12 months (TM Doberczak ...
As cocaine continues to be widely available in the USA (Medical Letter, 28:69, 1986), new problems associated with its use continue to emerge. Some recent reports indicate that use of the drug during pregnancy can damage the fetus, lead to abortion or premature labor, and cause toxic effects in the newborn infant.
NovolinPen for Insulin Injection
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988 (Issue 782)
a day; if regular and NPH insulin are required at different times, only the cartridge
needs ...
The NovolinPen (Squibb - Novo) is a device that uses prefilled cartridges to inject semisynthetic human insulin (Medical Letter, 25:63, 1983). Three formulations are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70% NPH and 30% regular (Novolin 70/30 PenFill). The NovolinPen is advertised as more accurate, more convenient and less expensive than conventional syringes and needles. The same device is marketed in Canada as the Novolin-Pen II (Connaught Novo). (An earlier device is also available as the Novolin-Pen in Canada and the...
Dezocine
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990 (Issue 829)
days.
ADVERSE EFFECTS — Nausea, vomiting, and sedation occur with dezocine about as often ...
Dezocine (Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine (Talwin), was recently approved for parenteral use as an analgesic by the US Food and Drug Administration.
Pegaspargase for Acute Lymphoblastic Leukemia
The Medical Letter on Drugs and Therapeutics • Mar 17, 1995 (Issue 944)
) or subcutaneously (SC) every 14 days. Some patients may require weekly
treatment. Asparaginase from E. coli ...
Pegaspargase (peg as par jase; PEG-L-asparaginase; Oncaspar - Rh ne-Poulenc Rorer), a polyethylene glycol (PEG) conjugate of L-asparaginase, has been approved by the US Food and Drug Administration for treatment of acute lymphoblastic leukemia (ALL), the most common malignancy of childhood. The new drug is recommended only for patients who have had allergic reactions to asparaginase. Asparaginase is available commercially as Elspar, which is derived from Escherichia coli. A formulation derived from Erwinia chrysanthemi is available on an investigational basis (Ogden Bioservices,...
Abciximab to Prevent Vessel Closure After Angioplasty
The Medical Letter on Drugs and Therapeutics • Jun 09, 1995 (Issue 950)
received intravenous heparin and oral aspirin. The primary endpoint was the occurrence within 30 days after ...
Abciximab (ab sik si mab; ReoPro - Centocor), the Fab (fragment antigen binding) fragment of the chimeric human-murine monoclonal antibody 7E3 (c7E3 Fab), has been approved by the US Food and Drug Administration as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) to prevent abrupt closure of the treated coronary vessel.
Epoprostenol for Primary Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996 (Issue 968)
administration, including two pumps, are also provided by Quantum, at the cost of $108.68 per day. The total ...
Epoprostenol sodium (Flolan - Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension.
Ibutilide
The Medical Letter on Drugs and Therapeutics • Apr 12, 1996 (Issue 972)
tachycardia) were excluded. In 200 patients with recent onset
(three hours to 90 days) of atrial fibrillation ...
Ibutilide fumarate (Corvert - Pharmacia & Upjohn), a new antiarrhythmic drug for intravenous use, has been approved by the US Food and Drug Administration for acute termination of atrial fibrillation or flutter of recent onset.
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997 (Issue 1004)
− Betaseron (Berlex) 8 million units every other day SC 10,980
* Cost to the pharmacist for one year’s ...
Glatiramer acetate (Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (MS). Interferon β-1b (Betaseron) and interferon β-1a (Avonex - Medical Letter, 38:63, 1996) were previously approved for this indication.